Specific reversal agent, Praxbind® (idarucizumab)1

Pradaxa® is the only NOAC with a specific reversal agent, Praxbind®, for emergency surgery/urgent procedures and life-threatening or uncontrolled bleeding.1

Praxbind® provides the reassurance of immediate, complete and sustained reversal
of the anticoagulant effects of Pradaxa® in emergency situations1–3

  • A fixed ready-to-use IV dose of 5g for all patients1
  • No prothrombotic effect1
  • Pradaxa® can be restarted after 24 hours, if clinically appropriate1

Praxbind® mode of action

Idarucizumab is a humanised monoclonal antibody fragment (Fab) that binds to dabigatran with very high affinity. Idarucizumab potently and specifically binds to dabigatran and its metabolites and neutralises their anticoagulant effect.1

Click below to watch the mode of action of Praxbind®, the specific reversal agent
for Pradaxa®1